Home > Boards > US Listed > Biotechs > OvaScience, Inc. (OVAS)

OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Golden_Cross Member Profile
Member Level 
Followed By 2,282
Posts 58,593
Boards Moderated 44
Alias Born 10/05/05
160x600 placeholder
Golden_Cross Member Level  Monday, 03/12/18 10:57:20 PM
Re: None
Post # of 71 
OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Date : 03/12/2018 @ 4:02PM
Source : Business Wire
Stock : Ovascience Inc. (OVAS)
Quote : 1.06 0.04 (3.92%) @ 8:00PM

OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Print
Alert
Ovascience Inc. (NASDAQ:OVAS)
Intraday Stock Chart
Today : Monday 12 March 2018

Click Here for more Ovascience Inc. Charts.
OvaScienceSM, Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced the grant of an inducement award to its newly appointed Chief Scientific Officer, James W. Lillie, Ph.D. The award was approved by OvaScience’s Board of Directors on March 6, 2018 as an inducement material to Dr. Lillie entering into employment with the Company, as permitted under Nasdaq Listing Rule 5635(c)(4). The inducement grant to Dr. Lillie consisted of an option to purchase up to 357,057 shares of common stock. The stock options are exercisable at a price of $1.02 per share, equal to the closing price per share of OvaScience’s common stock as reported by Nasdaq on March 6, 2018. The stock options vest over four years, with 25% of such options vesting on January 16, 2019 and 6.25% of such options vesting at the end of each subsequent quarter thereafter, subject to Dr. Lillie’s continued service with the Company through the applicable vesting dates.

About OvaScience
OvaScienceSM, Inc. (NASDAQ:OVAS) is a fertility company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC?) cells – immature egg cells found within the outer ovarian cortex. OvaScience is developing the OvaPrime? treatment, which could increase a woman’s egg reserve and the OvaTure? treatment, a potential in vitro fertilization (IVF) treatment that could help a woman produce new fertilizable eggs without hormone injections. OvaScience’s AUGMENT? treatment is a fertility option designed to improve IVF success rates. OvaScience treatments are not available in the United States. For more information, visit www.ovascience.com.

###



View source version on businesswire.com: http://www.businesswire.com/news/home/20180312005811/en/

Media and Investor Contact:
OvaScience, Inc.
Jennifer Viera, 617-420-8748
jviera@ovascience.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences